Survival for children and young people with acute lymphoblastic leukaemia (ALL) is high, but in those where the disease comes back after treatment, the prognosis isn’t as good. Developing new treatments for relapsed ALL is notoriously difficult, mainly because relapse is rare. This means that patients are missing out on effective treatments due to a lack of information to guide their therapy. Dr Marc Mansour and his team aim to address this problem by establishing a nationwide study analysing patient samples and uncovering the cancer’s genetics to guide which treatments the patients receive, giving them the best chance of survival.
This project is co-funded with Cancer Research UK as part of the Cancer Research UK–Children with Cancer UK Innovation Awards. Children with Cancer UK has contributed £483,311.35 towards this research project, the total cost of the project is £966,622.70
Improving outcomes for children whose leukaemia relapses after treatment
Dr David O’Connor, Professor Marc Mansour and Dr Jack Bartram
University College London Cancer Institute and Great Ormond Street Institute of Child Health
London, WC1E 6BT